Previously, we synthesized a series of hydrazide class ofcompounds and examined their cytotoxicity in a number ofcancer cell lines. Among these analogues, SC144 exhibitedpotent cytotoxicity against a panel of drug-sensitive anddrug-resistant cancer cell lines. To further explore itstherapeutic potentials in the combination settings, weevaluated the synergy between SC144 and selectedconventional chemotherapeutic agents in in-vitro cancercell models. SC144 showed synergism with both5-fluorouracil and oxaliplatin when cotreated in colorectalcancer HT29 cells. Pretreatment with SC144 inoxaliplatin-resistant HTOXAR3 cells was more effectivethan oxaliplatin pretreatment. In addition, thecombination of SC144 and paclitaxel exhibited synergismin MDA-MB-435 cells with a schedule-dependent block incell cycle. In an MDA-MB-435 mouse xenograft model,coadministration of SC144 and paclitaxel delayed tumorgrowth in an SC144 dose-dependent manner. Evaluationof the pharmacokinetics of SC144 revealed thatintraperitoneal administration of SC144 showed atwo-compartmental pharmacokinetics elimination profilethat was not observed in the oral dosing. In summary,these studies further validate SC144 as a novel anticanceragent and provide insights for developing combinationtherapies for both drug-sensitive and drug-resistantcancers.

Combination effects of SC144 and cytotoxic anticancer agents

GRANDE, Fedora;GAROFALO, Antonio;
2009-01-01

Abstract

Previously, we synthesized a series of hydrazide class ofcompounds and examined their cytotoxicity in a number ofcancer cell lines. Among these analogues, SC144 exhibitedpotent cytotoxicity against a panel of drug-sensitive anddrug-resistant cancer cell lines. To further explore itstherapeutic potentials in the combination settings, weevaluated the synergy between SC144 and selectedconventional chemotherapeutic agents in in-vitro cancercell models. SC144 showed synergism with both5-fluorouracil and oxaliplatin when cotreated in colorectalcancer HT29 cells. Pretreatment with SC144 inoxaliplatin-resistant HTOXAR3 cells was more effectivethan oxaliplatin pretreatment. In addition, thecombination of SC144 and paclitaxel exhibited synergismin MDA-MB-435 cells with a schedule-dependent block incell cycle. In an MDA-MB-435 mouse xenograft model,coadministration of SC144 and paclitaxel delayed tumorgrowth in an SC144 dose-dependent manner. Evaluationof the pharmacokinetics of SC144 revealed thatintraperitoneal administration of SC144 showed atwo-compartmental pharmacokinetics elimination profilethat was not observed in the oral dosing. In summary,these studies further validate SC144 as a novel anticanceragent and provide insights for developing combinationtherapies for both drug-sensitive and drug-resistantcancers.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11770/131013
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact